Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051884 | 1.00 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL29367967 | 1.00 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16683369 | 0.80 | NPSR1 (0.45) | HCAR2KEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL669238 | 0.80 | HCAR2 (0.37) | HCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL6442161 | 0.76 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10885715 | 0.75 | ALDH1A1 (0.50) | HCAR2KEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10889601 | 0.75 | ALDH1A1 (0.44) | HCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL10885717 | 0.75 | ALDH1A1 (0.50) | HCAR2KEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10889611 | 0.75 | ALDH1A1 (0.44) | HCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL16684429 | 0.75 | HTT (0.39) | HCAR2KEAP1NFE2L2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635995-B | Bicyclic compounds as ATX inhibitors | 豪夫迈·罗氏有限公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3353180-B1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2022-03-16 | — | — | EP | disclosed |
| EP-3353181-B1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-10889588-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200291038-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10738053-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200079779-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-03-12 | — | — | US | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| EP-3353181-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| WO-2017050747-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050732-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
| US-9102877-B2 | Systems and methods for producing fuels from biomass | SARTEC CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| US-20100170147-A1 | SYSTEMS AND METHODS FOR PRODUCING FUELS FROM BIOMASS | SARTEC CORPORATION | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HCAR2 222/4885KEAP1 2414/4885NFE2L2 1541/4885 |
| US-20200079779-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN10, ATXN2L | HCAR2 4359/4885KEAP1 421/4885NFE2L2 4543/4885 |
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN10, ATXN2L | HCAR2 4281/4885KEAP1 167/4885NFE2L2 4431/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HCAR2 222/4885KEAP1 2414/4885NFE2L2 1541/4885 |
| US-20200291038-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | HCAR2 3706/4885KEAP1 702/4885NFE2L2 4264/4885 |
| US-10738053-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | HCAR2 3706/4885KEAP1 702/4885NFE2L2 4264/4885 |
| US-10889588-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | HCAR2 3706/4885KEAP1 702/4885NFE2L2 4264/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | HCAR2 222/4885KEAP1 2414/4885NFE2L2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.